FierceBiotech RELATED: Keytruda keeps fueling Merck’s run, but...

FierceBiotech


RELATED: Keytruda keeps fueling Merck’s run, but CEO Frazier not ‘comfortable’ with future growth prospects
Frazier and co. are looking for ways to bolster Merck’s growth prospects, which largely revolve around superstar immuno-oncology agent Keytruda. While the company has inked a couple of well-regarded oncology partnerships—securing it half-ownership of AstraZeneca’s Lynparza and Eisai’s Lenvima—investors are still looking for broader diversification from the pharma giant.

Lots happening in the Biotec space for sure . Products dont have a forever life , and new technologies eclipse the old .

IMU could be on the verge of multiple licencing deals , IF the industry accept the validity of what they are doing .

Many years ago no one had heard of pennecilin . Imagin what a discovery like that would be worth today
IMU's B Cell IP is a potential game changer & will devalue a lot of the Big Pharma products .

Is Big Pharma gunna sit around and watch ?

I dont think so .